Kyoto Hospital to Test Using Ips Cells to Treat Diabetes; Seeks to Reduce Burden of Multiple Daily Insulin Injections The Japan News
Read the rest here:
Related Post
- A remarkable study was released this week. It is a Japanese researcher's paper that restored vision - - November 18th, 2024
- World's first stem cell treatment restores vision, offers new hope to the blind - India Today - November 12th, 2024
- The Breakthroughs of Vision Restoration - The New Importance of Stem Cells - Yahoo News UK - November 12th, 2024
- Modified stem cell therapy aids motor function in mice with... - Parkinson's News Today - October 30th, 2024
- Team achieves successful reproduction of hematopoietic stem cell developmental process in an in vitro culture system - Phys.org - October 22nd, 2024
- Human Pluripotent Stem Cells (iPSC) Generation, Culture, and ... - October 11th, 2024
- Induced pluripotent stem cell technology: a decade of progress - October 11th, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 10th, 2024
- Human Induced Pluripotent Stem Cells : Clinical Significance and ... - October 6th, 2024
- Induced pluripotent stem cells: Mechanisms, achievements and ... - October 6th, 2024
- Induced pluripotent stem cells | UCLA BSCRC - October 6th, 2024
- Unlocking new regenerative pathways in iPS cellderived epicardium for cardiac repair - Medical Xpress - October 4th, 2024
- Artificial heart made of iPS cells unveiled to press, to be displayed at 2025 Osaka expo - The Mainichi - The Mainichi - October 2nd, 2024
- Trial planned on sparing diabetes patients from insulin injections - - September 30th, 2024
- Leveraging the power of iPS cell technology to study myeloid neoplasm - Medical Xpress - September 10th, 2024
- Kyoto University Hospital seeks to treat Type 1 diabetes using iPS cells - The Japan Times - September 4th, 2024
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - August 24th, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine - August 24th, 2024
- Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - August 24th, 2024
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 - August 24th, 2024
- Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow - August 24th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 24th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - August 24th, 2024
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - August 24th, 2024
- Novel insights from Human Induced Pluripotent Stem Cells on Origins and Roles of Fibro/Adipogenic Progenitors as Heterotopic Ossification Precursors -... - August 22nd, 2024
- Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity -... - August 18th, 2024
- Culture Techniques for Drug Discovery and Therapeutics - Technology Networks - August 16th, 2024
- iPSC culture techniques for drug discovery and therapeutics - Labmate Online - August 12th, 2024
- Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs - Frontiers - August 6th, 2024
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 31st, 2024
- Purification technologies for induced pluripotent stem cell therapies - Nature.com - July 28th, 2024
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results - July 26th, 2024
- Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research - July 26th, 2024
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - July 26th, 2024
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 - July 26th, 2024
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 - July 26th, 2024
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study - July 26th, 2024
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - July 26th, 2024
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 - July 26th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 - July 26th, 2024
- Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia - July 26th, 2024
- scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic... - July 26th, 2024
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 - July 26th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - July 26th, 2024
- Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - July 26th, 2024
- Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment... - July 26th, 2024
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health... - July 26th, 2024
- Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 - July 26th, 2024
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support - July 26th, 2024
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - July 26th, 2024
- ISSCR 2024: iPS cell line panels can be isogenic and diverse - BioWorld Online - July 16th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - PR Newswire - July 10th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - The Manila Times - July 10th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - July 5th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Monthly information on share capital and company voting rights - July 5th, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Integrating organoids and organ-on-a-chip devices - Nature.com - July 4th, 2024
- Very small embryonic-like stem cells have the potential to win the three-front war on tissue damage, cancer, and aging - Frontiers - July 2nd, 2024
- The progress of induced pluripotent stem cells derived from pigs: a mini review of recent advances - Frontiers - June 30th, 2024
- Regeneration of T cells from human-induced pluripotent stem cells for CAR-T cell medicated immunotherapy - Frontiers - June 30th, 2024
- Induced pluripotent stem cells in companion animals: how can we move the field forward? - Frontiers - June 28th, 2024
- Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes A Tool to Study ... - Frontiers - June 28th, 2024
- The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor ... - Frontiers - June 26th, 2024
- Neural Stem Cells and Methods for Their Generation From Induced Pluripotent Stem Cells in vitro - Frontiers - June 26th, 2024
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz Program with the ... - StockTitan - June 26th, 2024
- Unraveling the Mystery of Atherosclerosis in Patients with Werner SyndromeNews & Events | CiRA | Center for iPS ... - - June 19th, 2024
- Shinobi and Anocca to advance cancer killing iPS-T cell therapies - BioProcess Insider - May 31st, 2024
- Startup to Apply For Approval to Produce Heart Cell Sheets from iPS Cells for Heart Disease Treatment - The Japan News - May 27th, 2024
- Japan startup to seek approval for iPS cell therapy in global first - Nikkei Asia - May 25th, 2024
- Improving the safety of iPS cell-derived pancreatic islets by eliminating unwanted cells - Medical Xpress - May 15th, 2024
- Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes - Nature.com - May 15th, 2024
- Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC ... - GlobeNewswire - May 8th, 2024
- Human iPSCs restore muscle, function in monkeys with heart failure - BioWorld Online - May 4th, 2024
- Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing ... - PR Newswire - April 24th, 2024
Recent Comments